Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clinical trials, alone or in combination with JAK2 inhibitors. Patients with myelofibrosis should be encouraged to participate in clinical trials testing novel compounds for this disorder, particularly if they have failed a trial of JAK2 inhibitors.
|
Authors | Fabio P S Santos, Srdan Verstovsek |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 20
Issue 2
Pg. 123-9
(Mar 2013)
ISSN: 1531-7048 [Electronic] United States |
PMID | 23385614
(Publication Type: Journal Article, Review)
|
Chemical References |
- Protein Kinase Inhibitors
- Janus Kinase 2
|
Topics |
- Humans
- Janus Kinase 2
(antagonists & inhibitors)
- Primary Myelofibrosis
(drug therapy)
- Protein Kinase Inhibitors
(therapeutic use)
|